Dubow Adam's Form 4 filing
Day One Biopharmaceuticals, Inc. (DAWN) · filed Aug 19, 2024
- Accession no.
- 0001415889-24-021629
- Filed
- Aug 19, 2024
- Trade date
- Aug 15-16, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $44.8K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dubow AdamCIK 0001744507 | Officer (GENERAL COUNSEL) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 15, 2024 | Common Stock | MOption exerciseAcquired | +2,962 | – | – | 24,693 | Direct | |
| Aug 15, 2024 | Common Stock | MOption exerciseAcquired | +1,750 | – | – | 26,443 | Direct | |
| Aug 15, 2024 | Common Stock | MOption exerciseAcquired | +3,687 | – | – | 30,130 | Direct | |
| Aug 16, 2024 | Common Stock | SSaleDisposed | −3,202 | $14.00 | −$44,828 | 26,928 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 15, 2024 | Common Stock | MOption exerciseDisposed | −2,962 | $0.00 | $0 | 26,664 | Direct | |
| Aug 15, 2024 | Common Stock | MOption exerciseDisposed | −1,750 | $0.00 | $0 | 15,750 | Direct | |
| Aug 15, 2024 | Common Stock | MOption exerciseDisposed | −3,687 | $0.00 | $0 | 47,939 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.